Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 5,022 shares, an increase of 7,746.9% from the January 15th total of 64 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 209,694 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 209,694 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Enzon Pharmaceuticals Price Performance

ENZN stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.06. 208 shares of the stock were exchanged, compared to its average volume of 81,686. The stock has a market capitalization of $4.79 million, a price-to-earnings ratio of -1.29 and a beta of 0.19. Enzon Pharmaceuticals has a 12 month low of $0.03 and a 12 month high of $0.17. The business has a fifty day moving average price of $0.05 and a 200 day moving average price of $0.06.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.02) EPS for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.